Evidence map›Paper›PMID 41613856›Full record

ArticleBiotechnologia2025

Gene expression, purification, and functional characterization of recombinant conotoxin μ-TIIIA and TIIIAlaMut in

Diana Mikiewicz, Anna Mazurkiewicz-Pisarek, Magdalena Janczewska, Jolien De Waele, Alina Mazurkiewicz, Agata Stefanek, Frank Bosmans, Agnieszka Lew-Mirska, Przemysław Styczeń, Tomasz Ciach

Abstract read
In one paragraph

Article in Biotechnologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Diana MikiewiczScience4Beauty LLC, Warsaw, Poland.
Anna Mazurkiewicz-PisarekScience4Beauty LLC, Warsaw, Poland.
Magdalena JanczewskaScience4Beauty LLC, Warsaw, Poland.
Jolien De WaeleMolecular Physiology and Neurophysics Group, Department of Basic and Applied Medical Sciences, Faculty of Medicine and Health Sciences, University of Gent, Gent, Belgium.
Alina MazurkiewiczScience4Beauty LLC, Warsaw, Poland.
Agata StefanekScience4Beauty LLC, Warsaw, Poland.
Frank BosmansMolecular Physiology and Neurophysics Group, Department of Basic and Applied Medical Sciences, Faculty of Medicine and Health Sciences, University of Gent, Gent, Belgium.
Agnieszka Lew-MirskaSelf Esteem Aesthetic Clinic LLC, Warsaw, Poland.
Przemysław StyczeńAesthetic Medicine Clinic, Warsaw, Poland.
Tomasz CiachScience4Beauty LLC, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Conotoxins are small peptides known for their potent and selective activity on ion channels, offering potential applications in both medicine and cosmetology. This study aimed to design and validate recombinant conotoxin TIIIA and its mutant TIIIAlaMut, assess their biological activity on the voltage-gated Na Materials and methods: Fusion genes encoding Results: Both recombinant genes were successfully expressed, purified, and activated. Electrophysiological measurements demonstrated their ability to inhibit Nav1.4 channel activity, including the version extracted directly from the cream. In the human study, 47% of participants reported a visible reduction in wrinkles. Additional benefits included evening of skin tone, reduced erythema, and balanced sebum production in oily skin types. Conclusion: This study describes the design, bacterial expression, and functional analysis of recombinant conotoxins TIIIA and TIIIAlaMut. Their bioactivity was confirmed on human Nav1.4 channels. The recombinant toxins, including the form extracted from the cream, showed effects comparable to a synthetic standard. Application tests demonstrated the conotoxin's potential in cosmeceuticals, particularly in reducing periocular wrinkles and improving skin texture and tone.

Indexed as

antiaging activityconotoxinsEscherichia coli expression systempatch-clamp methodrecombinant protein production

Identifiers

PMID41613856
PMCPMC12848868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.